



NewsBREAK | April 17

CMS Issued CY 2024 Part D Formulary Submission Information

On April 14, 2023, CMS issued the CY 2024 Part D Formulary Submission Information memo to assist Part D sponsors with the submission of Contract Year (CY) 2024 formularies.

Important dates regarding the CY 2024 formulary submission:

- May 15, 2023 — release of the CY 2024 HPMS Formulary Submission Module
- June 5, 2023 at 11:59pm PDT — Deadline for the following submissions:
 - Initial formulary submission
 - Transition attestation and policy submission
 - Formulary attestations (Pharmacy and Therapeutics Committee and Prior Authorization/Step Therapy)
 - Formulary crosswalk
- June 7, 2023 — file submission window for the Supplemental formulary and Additional Demonstration Drug (ADD) opens.
- June 9, 2023 11:59am EDT — Supplemental formulary and ADD file submission deadline.
- On or about June 12, 2023 — Stage 1 review concerns.
- On or about June 30, 2023 — Stage 2 review concerns.
- On or about July 19, 2023 — Stage 3 review concerns.
- Early August 2023 — Summer limited formulary update window.
- Late September 2023 — Formulary update window for limited enhancements and generic substitutions only.

See the HPMS memo for additional information.

More on This Topic

- [HPMS memo](#)

For questions, please reach out to [Tyler Thorne](#).